omation mbers - Society for Laboratory Automation and Screening

5:00 pm Wednesday, February 4 Emerging Technologies – Automation Systems Room A3
Jaymie Sawyer
Dyax Corporation
109754 Torreyana Road, W-1
San Diego, California 92121
jsawyer@dyax.com
Managing Automated RFLP Analysis in Phage Display Antibody Screening
135
Co-Author(s)
I-wei Feng, Lee A. Morganelli,
Rosanto Paramban, Roger Dettloff,
Irina Mineyev, Paul Kotturi
Caliper Technologies Corporation
Automated screening of Dyax’s proprietary human Fab library is currently in use to discover new antibodies
and develop research reagents in collaboration with BD Biosciences. PCR fingerprinting is a useful tool in the
analysis of clones derived from large libraries containing similar sized inserts. The fingerprints allow us to assess
the diversity in pools of selected phage before moving into high throughput screening, or to avoid repeated
expression and purification of the same clone. Vector-specific primers amplify the insert which is then digested
with a frequently cutting restriction enzyme. Typically, gel electrophoresis is then used to visualize RFLPs. The
Caliper AMS 90 SE system allows 96-384 digested DNA samples to be analyzed without running or photographing
gels. The series of DNA fragments within a given sample are identified by LabChip HT software. To fully exploit
fingerprinting, the data output must allow comparison of digests run at different times and facilitate correlation of
clone identity with functional assays. These final data handling procedures are tedious and not automated. We
developed a software tool to analyze the results from an AMS 90 SE and automate the final clone identification.
DNA fragments between 50 and 500 base pairs are binned into groups between 15 and 20 bps. The peaks within
a group are assigned a letter of the alphabet, resulting in a clone ‘name’. The resulting clone names can then be
exported and correlated with functional assays such as expression levels and ELISA performance to identify new
antibodies generated by phage display.
5:15 pm Wednesday, February 4 Emerging Technologies – Automation Systems Room A3
David Semin
Amgen, Inc.
One Amgen Center Drive, Mailstop 29-M-B
Thousand Oaks, California 91320
dsemin@amgen.com
The Next Generation of a Compound Management System in Drug Discovery
Co-Author(s)
Janet Cheetham, Stewart Chipman,
Peter Grandsard, Colin McRavey,
Sabrina Park, Jim Petersen
As the competition in drug discovery intensifies companies need to become more operationally efficient and to
maximize return on investment. Since the emergence of automated compound storage and retrieval systems in the
1990s there has been considerable progress on overall compound management strategies to facilitate compound
flow throughout research operations. Some of these recent strategies have evolved around the new market of
small to medium sized storage and retrieval systems. In an effort to fully enable Amgen’s global lead discovery
efforts we are developing a compound management system based on a modular and multi-tier approach with
the concept of archival and operational compound stores. The modularity enables flexibility and incorporation
of new technology platforms, while the multi-tier approach enables redundant and priority storage formats. A
system of operational stores will fuel the chemistry and high throughput screening activities, while an archival
store will be used ensure long-term compound quantity and quality. A global software infrastructure solution
with generic interfaces to the modular components will be presented. The infrastructure is designed to enable
excellence at compound collection stewardship while maintaining flexibility for change in business processes
and the incorporation of new technology platforms. This drive towards the next generation system built upon
these hardware and software concepts should enable a compound management system in drug discovery to be
operationally efficient and effectively stay off the critical path and timeline for research programs.
PODIUM ABSTRACTS